For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126 (Public Relations)
+81-3-6225-1125 (Investor Relations)
http://www.daiichisankyo.com/

Announcement on Change in Ranbaxy Executive Leadership

TOKYO, Japan (August 12, 2010) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the Board of Directors of Ranbaxy Laboratories Limited (hereafter, Ranbaxy), the Indian subsidiary of Daiichi Sankyo, has decided to make change in its executive leadership.

 

Mr. Atul Sobti will step down from the positions of CEO and Managing Director of Ranbaxy, effective August 19, 2010, and Mr. Arun Sawhney, currently Ranbaxy's President, Global Pharmaceuticals Business, will be appointed as Managing Director, effective August 20, 2010.

 

Daiichi Sankyo acknowledges the significant contribution made by Mr. Sobti during his tenure as CEO and MD, as well as his leadership in building upon the strong legacy of Ranbaxy as a premier global company.

 

Through the appointment of Mr. Sawhney, Daiichi Sankyo and Ranbaxy will further enhance and strengthen their collaborative relationship to realize the innovative Hybrid Business Model.